Research programme: dermatologic disorder therapeutics - Takeda

Drug Profile

Research programme: dermatologic disorder therapeutics - Takeda

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Takeda Pharma
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Skin disorders

Most Recent Events

  • 12 Sep 2016 Early research in Skin disorders in Japan (Topical)
  • 12 Sep 2016 Dermira and Takeda Pharma enter into an option and license agreement for dermatologic disorder therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top